Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer.

Journal of experimental & clinical cancer research : CR - 20 Nov 2024

Novoplansky Ofra, Jagadeeshan Sankar, Prasad Manu, Yegodayev Ksenia M, Marripati Divyasree, Shareb Raghda Abu, Greenshpan Yariv, Mathukkada Sooraj, Ben-Lulu Talal, Bhattacharya Baisali, Porgador Angel, Kong Dexin, Brägelmann Johannes, Gutkind J Silvio, Elkabets Moshe

Abstract excerpt

BACKGROUND: Basket clinical trials targeting the KRASG12C-mutation in solid tumors have shown initial promise, including in orphan KRASG12C head and neck cancer (HNC). However, development of resistance to KRASG12C-mutant-specific inhibitors (KRASG12Ci) remains a major obstacle. Here, we investigated the intrinsic (tumor-cell autonomus) and tumor-microenvironment (TME) mechanisms of resistance to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Head and Neck Neoplasms

Share to Mutation

Share to Programmed Cell Death 1 Receptor

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 39567998
DOI: 10.1186/s13046-024-03227-0
PMCID: PMC11577641

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer.PMID 39567998Read ↗

Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culpritSemantic proximity Read ↗

The quest to overcome resistance to EGFR-targeted therapies in cancer.Semantic proximity Read ↗

Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in <i>KRAS</i> -mutant Pancreatic and Lung CancerSemantic proximity Read ↗

Targeting AXL Overcomes Adaptive Resistance to KRAS Inhibition in KRAS-Driven CancerSemantic proximity Read ↗

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies.Semantic proximity Read ↗

An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapySemantic proximity Read ↗

RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activationSemantic proximity Read ↗

A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal CancerSemantic proximity Read ↗

Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models.Semantic proximity Read ↗

SHP2 Inhibition Abrogates Adaptive Resistance to KRAS <sup>G12C</sup> -Inhibition and Remodels the Tumor Microenvironment of <i>KRAS</i> -Mutant TumorsSemantic proximity Read ↗

Efficacy of RMC-6236 (Daraxonrasib) and novel combination strategies targeting resistance in RAS pathway-driven neuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.